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Somatostatin Receptor 2A Expression in Choroidal
Neovascularization Secondary to Age-Related
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Mike Kliffen,3 G. Seerp Baarsma,4 P. Martin van Hagen,2 and Cornelia M. Mooy1,3,5
PURPOSE. The growth of ocular neovascularization is regulated by a balance between stimulating and
inhibiting growth factors. Somatostatin affects angiogenesis by inhibiting the growth hormone–
insulin-like growth factor axis and also has a direct antiproliferative effect on human retinal
endothelial cells. The purpose of our study is to investigate the expression of somatostatin receptor
(sst) subtypes and particularly sst subtype 2A (sst2A) in normal human macula, and to study sst2A
in different stages of age-related maculopathy (ARM), because of the potential anti-angiogenic effect
of somatostatin analogues.
METHODS. Sixteen eyes (10 enucleated eyes, 4 donor eyes, and 2 surgically removed choroidal
neovascular [CNV] membranes) of 15 patients with eyes at different stages of ARM were used for
immunohistochemistry. Formaldehyde-fixed paraffin-embedded slides were incubated with a poly-
clonal anti-human sst2A antibody. mRNA expression of five ssts and somatostatin was determined
in the posterior pole of three normal human eyes by reverse transcriptase–polymerase chain
reaction.
RESULTS. The immunohistochemical expression of sst2A in newly formed endothelial cells and
fibroblast-like cells was strong in fibrovascular CNV membranes. mRNA of sst subtypes 1, 2A, and
3, as well as somatostatin, was present in the normal posterior pole; sst subtypes 4 and 5 were not
detectable.
CONCLUSIONS. Most early-formed CNV in ARM express sst2A. The presence of mRNA of sst subtype
2A was observed in normal human macula, and subtypes 1 and 3 and somatostatin are also present.
sst2A receptors bind potential anti-angiogenic somatostatin analogues such as octreotide. Therefore,
somatostatin analogues may be an effective therapy in early stages of CNV in ARM. (Invest
Ophthalmol Vis Sci. 2000;41:2329–2335)
Age-related maculopathy (ARM) is the major cause ofblindness in people more than 65 years of age in theWestern world. The prevalence of ARM is up to 14% in
people aged more than 85 years.1 Late stages of ARM, also
called age-related macular degeneration (AMD), include geo-
graphic atrophy and exudative macular degeneration. The ex-
udative form is characterized by choroidal neovascularization
(CNV) and is responsible for 80% of cases of severe vision loss.1
These numbers will increase because of the increasing age of
the population. In CNV, newly formed vessels from the under-
lying choroid grow beneath the retinal pigment epithelium
(RPE) and the retina.2 Although the morphology of angiogen-
esis in CNV secondary to AMD has been described in detail, the
pathogenesis is still poorly understood. A balance between a
number of stimulating and inhibiting growth factors regulates
the growth of neovascularization.2 Vascular endothelial growth
factor (VEGF), an endothelium-specific mitogen, is regarded as
one of the most important ocular angiogenic factors, especially
in ischemic disease.2–8 Other regulating growth factors include
fibroblast growth factors (FGFs), transforming growth factor
(TGF)-b and insulin-like growth factor (IGF)-I. Most of these
growth factors are shown to be upregulated in a diversity of
cells (RPE, fibroblasts, capillary endothelial cells) involved in
CNV.4,5,9–13
Recently, it has been shown in a transgenic mouse model
that inhibition of growth hormone (GH), mediated by IGF-I,
can inhibit ischemia-induced retinal neovascularization in
vivo.14 GH secretion is inhibited by somatostatin and soma-
tostatin analogues. Systemic treatment with a somatostatin
analogue diminished the level of ocular neovascularization in
mice.14
Somatostatin binds with high affinity to five subtype re-
ceptors (sst types 1 to 5). These receptors were identified in
various animal retinas.15–17 The exact role of a direct receptor-
mediated effect by somatostatin analogues is still unknown. To
date, information about sst2 receptor expression in CNV is not
available, and until now sst subtype expression has not been
described in normal human retina.
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The purpose of our study was to investigate the expres-
sion of sst2A in different stages of ARM and the expression of
sst subtypes and somatostatin in normal human macula.
MATERIALS AND METHODS
The study was performed according to the tenets of the Dec-
laration of Helsinki. Enucleation or surgical excision of subfo-
veal CNVs was performed after obtaining informed consent of
the patient.
Patients
All eyes were retrieved from the files from the Ophthalmic
Pathology Department of the University Hospital of Rotterdam.
Sixteen eyes (10 enucleated eyes, 4 donor eyes, and 2 surgi-
cally removed subretinal neovascular membranes) of 15 pa-
tients with eyes at different stages of ARM were used for
immunohistochemistry. The description of each eye is given in
Table 1. Eight eyes (of seven patients) had clinical diagnoses of
AMD. In eight other eyes, ARM was diagnosed histopatholog-
ically according to the following criteria: Early stages of ARM (n
5 3) were characterized by the presence of basal laminar
deposits, basal linear deposits (BLD), soft drusen, and thicken-
ing of Bruch’s membrane.18 Exudative AMD (n 5 12) was
classified as sub-RPE CNV, subretinal CNV (between neuro-
retina and RPE) or mixed sub-RPE and subretinal CNV.19,20
Photoreceptors, Bruch’s membrane, and BLD were helpful in
the orientation of the specimens.19 Sub-RPE CNV and mixed
CNV, or subretinal CNV in elderly patients in the presence of
BLD or soft drusen were classified as CNV secondary to AMD.19
In CNV, we recorded the presence of fibrovascular or fibrocel-
lular tissue, hemorrhage, vascular endothelium, BLD, and
RPE.19 One eye was classified as having nonneovascular (geo-
graphic) AMD. Eight enucleated eyes without ARM (donor eyes
or enucleated for other reasons) were used as controls (Table
2). The eyes were processed for routine diagnostic procedures
by fixation in formaldehyde and were embedded in paraffin.
Immunohistochemistry
Rabbit antihuman sst2A polyclonal antibody (R2-88) was kindly
provided by Agnes Schonbrunn (Department of Integrative
Biology and Pharmacology, University of Texas Houston Med-
ical School). The antibody was raised against a 22-amino acid
peptide located at the C-terminal region of the sst2 receptor.
The sst2A antibody had been characterized and tested before by
Western blot analysis and peptide binding.21,22 Mouse mono-
clonal antibody against smooth muscle actin (SMA) was ob-
tained from Biogenex (San Ramon, CA) and mouse monoclonal
antibody against macrophages (CD68) from Dako (Glastrup,
Denmark). Five-micrometer sections were prepared. The sec-
tions were deparaffinated, rehydrated, and (for sst2A and
CD68) microwave heated for 10 minutes. After the slides were
TABLE 1. Patient Data and sst2A Receptor Expression in Eyes with ARM
Age/Sex Eye Clinical Description Histological Classification
sst2A
Expression in
Preexistent
Tissue*
sst2A Expression in
Neovascular Tissue
Fibro-
vascular
Fibro-
cellular
RPE CC CH EC† FBL EC† FBL
1 85/M OS Necrotising sclerokeratomalacia Early ARM: BLD 11 0 11 NA NA NA NA
2 98/F OS Corneal ulcer Early ARM: confluent soft drusen 11 1 11 NA NA NA NA
3 96/F OD Staphyloma, suspected ciliary
body melanoma
Early ARM: BLD; glaucoma; corneal ulcer 11 0 1 NA NA NA NA
4 77/M OS Neovascular glaucoma Nonneovascular AMD, early geographic
atrophy; occlusion central retinal
artery; ischemic retinal disease
11 0 1 NA NA NA NA
5 73/M OD Disciform MD, after irradiation Subretinal CNV, FV 1 0 11 2/3 1 NA NA
6 85/F OS Postsurgical endophthalmitis Subretinal CNV, FV, endophthalmitis,
uveitis
1 0 1 2/2 1 NA NA
7 79/M U Surgically excised CNV Mixed CNV, FV and FC, HEM NP NP NP 37/48 11 NP 0
8 79/F U Surgically excised CNV Subretinal CNV, FV and FC, HEM NP NP NP 15/18 11 NP 11
9 72/M OS Disciform MD Mixed CNV, BLD, FV and FC, HEM 1 0 1 28/50 1 0/7 0
10 86/M OS Disciform MD, acute glaucoma Sub-RPE CNV, BLD, FV and FC, HEM;
retinal detachment; posterior uveitis
11 1 11 NP NP 2/4 11
11 87/M OS Donor eye Disciform MD, mixed CNV, BLD, FV and
FC
11 1 11 11/16 1 3/5 1
12 83/M OD Painful eye, suspected uveal
melanoma
Ischemic retinal disease; disciform MD,
mixed CNV, BLD, FV and FC, HEM
11 0 1 26/64 11 0/3 11
13 73/M OS Disciform MD Subretinal CNV, FC and FV 11 0 1 13/15 11 NC 1
14 84/F OS Disciform MD Mixed CNV, FV and FC, HEM 1 0 1 0/2 1 NC 0
15 91/M OS Donor eye Disciform MD, mixed CNV, BLD, FC NC 0 NC NA NA 0/6 1
16 82/M OD Disciform MD Mixed CNV, confluent soft drusen, FC 1 0 0 NA NA 13/36 0
MD, macular degeneration; mixed CNV, mixed subretinal and sub-RPE CNV; FV, fibrovascular CNV; FC, fibrocellular scar; BLD, basal laminar
deposits; HEM, hemorrhage. RPE, retinal pigment epithelium; CC, choriocapillaris; CH, choroidal vessels; CNV, choroidal neovascularization; EC,
endothelial cells; FBL, fibroblast-like cells; U, unknown; NC, not classifiable; NP, not present; NA, not applicable.
* Category of sst2A expression: 0 5 0%–10% positive cells; 1 5 11%–50% positive cells; 11 5 51%–100% positive cells.
† sst2A expression in endothelial cells in CNV was quantitatively determined by counting the proportion of positive vessels in randomly
selected sections.
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blocked with normal goat serum (Dako, 1:10) for 15 minutes,
they were incubated with the sst2A antibody (1:1000) or CD68
antibody (1:2000) overnight at 4°C or with anti-SMA (1:150) for
1 hour at room temperature. The sections were further incu-
bated with biotinylated multilink antibodies for 30 minutes,
followed by alkaline phosphatase–labeled anti-biotin (both
from Biogenex) for 30 minutes. The bound antibodies were
visualized by incubating the sections with new fuchsin for 30
minutes in the dark. The slides were counterstained with
Mayer’s hematoxylin, mounted, and examined by light micros-
copy. We determined the sst2A expression quantitatively in
endothelial cells of CNV by counting the proportion of positive
vessels in randomly selected sections. The total number of
counted vessels was pooled, and the proportions of positive
cells in fibrovascular and fibrocellular CNV were compared by
x2 analysis. For other tissue components, we semiquantita-
tively graded sst2A expression in three categories: 0 (0%–10%
positive cells), 1 (11%–50% positive cells), and 2 (51%–100%
positive cells). Negative controls for immunohistochemistry
included omission of the primary antibody, use of an irrelevant
antibody of the same isotype, and preabsorption of the sst2A
antibodies with the immunizing receptor peptide for 4 hours at
a concentration of 3 mg/ml.
Reverse Transcriptase-Polymerase Chain Reaction
To study the mRNA expression of sst subtypes in normal
human eyes, posterior poles from three eyes (Table 2) were
dissected directly after enucleation. A sample of approximately
0.2 mm2 located in the macula, including retina, RPE, choroid,
and sclera, was snap frozen in liquid nitrogen. Reverse tran-
scriptase–polymerase chain reaction (RT-PCR) was performed
as described before23 but with different primers (Table 3).
Several controls were included in the RT-PCR experi-
ments. To ascertain that no detectable genomic DNA was
present in the polyA1 mRNA preparation (because the sst
genes are intronless), the cDNA reactions were also performed
without reverse transcriptase and amplified with each primer
pair. Amplification of the cDNA samples with the hypoxan-
thine-guanine phosphoribosyl transferase (HPRT)–specific
primers served as positive control for the quality of the cDNA.
To exclude contamination of the PCR reaction mixtures, the
reactions were also performed in the absence of DNA template
in parallel with cDNA samples. As a positive control for the
PCR reactions of the sst receptor subtypes, 0.1 to 0.001 mg of
human genomic DNA, representing approximately 30.000 to
300 copies of sst-template, was amplified in parallel with the
cDNA samples. As a positive control for the PCR of HPRT and
somatostatin cDNA, aliquots of a cDNA sample known to
contain somatostatin and HPRT mRNA were amplified, be-
cause these primer pairs enclosed introns in the genomic DNA.
RESULTS
Immunohistochemistry
In normal retina (n 5 8) we found strong sst2A expression in
the inner plexiform layer and moderate expression in the outer
plexiform layer, the cellular membrane of the inner nuclear
layer (Fig. 1A), and the RPE. RPE stained most frequently at the
apical side in a membranous pattern (Fig. 1B), which was also
noted in tangentially cut sections. Thick-walled choroidal ves-
sels stained mostly positive, but choriocapillaris only sporadi-
cally (Table 1). In negative controls, no staining was detected.
In the eyes with early ARM (n 5 3), sst2A expression of the
neuroretina, choroidal vessels, and choriocapillaris was similar
to normal controls (Table 1). The RPE stained positive in all
cases. BLD were negative (Fig. 1C).
In eyes with exudative AMD (n 5 12), Bruch’s membrane
and BLD did not show sst2A expression (Table 1). The cho-
riocapillaris showed focal expression in only two eyes. Ap-
proximately 50% to 75% of thick-walled choroidal vessels
stained positive, which was similar to normal controls. The
CNV, both surgically excised and in enucleated eyes, could be
subdivided in three groups, according to the activity of neo-
vascularization. The first group consisted of fibrovascular tissue
TABLE 2. Patient Data and sst Receptor Subtype Expression in Normal Eyes
Age/Sex Eye Clinical Description
sst Receptor Subtype Expression*
(RT-PCR)
sst2A
Expression†
(Immuno-
histochemistry)
sst1 sst2A sst3 sst4 sst5 SS14 HPRT RPE CC CH
1 71/U OD Donor eye ND ND ND ND ND ND ND 11 1 11
2 51/M OD Ciliary body melanoma ND ND ND ND ND ND ND 1 0 1
3 78/M OS Choroidal melanoma ND ND ND ND ND ND ND 11 0 1
4 81/M OS Tarsal squamous cell carcinoma ND ND ND ND ND ND ND 1 1 11
5 42/M OS Choroidal melanoma ND ND ND ND ND ND ND 11 0 11
6 76/F OS Choroidal melanoma ND ND ND ND ND ND ND 11 0 11
7 57/M OS Recurrent conjunctival melanoma ND ND ND ND ND ND ND 1 0 1
8 60/M OS Choroidal melanoma ND ND ND ND ND ND ND 11 0 11
9 69/M OD Ciliary body adenoma 1 1 1 2 2 1 1 ND ND ND
10 78/M OS Spindle cell nevus 1 1 1 2 2 1 1 ND ND ND
11 26/M OS Choroidal melanoma 1 1 1 2 2 1 1 ND ND ND
SS14, somatostatin; HPRT, hypoxanthine-guanine phosphoribosyl transferase; RPE, retinal pigment epithelium; CC, choriocapillaris; CH,
choroidal vessels. U, unknown; ND, not done.
* Categories of sst subtype expression (RT-PCR): 2 5 no expression, 1 5 positive expression.
† Categories of sst2A expression (immunohistochemistry): 0 5 0–10% positive cells: 1 5 11%–50% positive cells; 11 5 51%–100% positive
cells.
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with inflammatory cells, fibroblast-like cells, and sparse fibrosis
(n 5 2). The second group consisted of fibrocellular scar tissue
(n 5 2), and the third group consisted of a mixture of both
fibrovascular and fibrocellular tissue (n 5 8).19
In the CNV, monolayers of pigmented cells adjacent to
BLD were scored as RPE cells. Approximately half of these
morphologically RPE cells showed sst2A expression. The ex-
pression of sst2A in newly formed endothelial cells was strong
in fibrovascular membranes. Similarly, sst2A was strongly ex-
pressed in endothelial cells of mixed fibrovascular and fibro-
cellular membranes (Fig. 1E, 1F, 1G). Fibroblast-like cells and
macrophages stained strongly positive in young membranes
and less strongly in older scars (Fig. 1E, 1G, 1H). Little or
negative staining was observed in old hypocellular scars (Fig.
1H). Expression in endothelial cells in fibrovascular mem-
branes (61.5%) was statistically significant more often than in
fibrocellular membranes (29.5%; x2 analysis, P , 0.001). Stain-
ing in CNV was considered specific, because peptide blocking
significantly decreased staining of all structures mentioned
(Fig. 1D).
In one eye with a mixed fibrovascular and fibrocellular
membrane (eye 12), we found positive staining of myofibro-
blasts in a hypercellular area of the underlying choroid in the
posterior pole. This area also stained positively with antibodies
directed against SMA and CD68, confirming the presence of
myofibroblasts and macrophages.
In the eye with nonneovascular AMD, the staining pattern
was similar to control tissue. The RPE stained positively. No
staining was seen in the choriocapillaris, and vessels in the
choroid were mostly positive.
Reverse Transcriptase-Polymerase Chain Reaction
RT-PCR analysis of three posterior poles, including retina, RPE,
choroid, and sclera, revealed that mRNA encoding for sst1,
sst2A, sst3, and somatostatin is expressed in the posterior pole
of normal human eyes. No mRNA encoding for sst4 or sst5 was
detected (Fig. 2, Table 2).
DISCUSSION
In the present study normal human eyes and eyes with early
and late stages of ARM expressed sst2A. The localization of sst2A
expression in the neuroretina is consistent with findings in
rabbit15 and rat16 retina and reflects the assumed physiological
neuromodulator function of somatostatin.24,25 In early stages
of ARM, the choroidal vasculature and neuroretinal tissue
stained identically with control tissue. We found no expression
of sst2A in BLD or drusen, which is in contrast with findings for
other angiogenic growth factors such as VEGF.3
In eyes with exudative AMD, we found strong expression
of sst2A in endothelial cells and fibroblast-like cells in early
CNV. The expression of sst2A in newly formed capillaries was
abundant in fibrovascular CNV membranes. Similarly, in the
active component of mixed fibrovascular–fibrocellular CNV,
sst2A was strongly expressed in endothelial cells. Grant et al.
26
demonstrated the presence of somatostatin receptors on cul-
tured human retinal endothelial cells. They showed a direct
inhibitory action of a somatostatin analogue on proliferation of
these endothelial cells. Therefore, the angiogenic cells of CNV
membranes may be capable of receiving angiogenic inhibition,
directly receptor mediated or indirectly through inhibition of
GH and IGF-I by somatostatin. In mice retina, somatostatin
analogues have an inhibitory effect on neovascularization.14
Somatostatin analogues, such as the long-acting octreotide,
which binds to somatostatin receptor subtypes 2 and 5, are
used as experimental treatment in neovascular eye diseases
such as diabetic retinopathy.27–29
We found strong sst2A expression in fibroblast-like cells
and macrophages in fibrovascular CNV and in intrachoroidal
myofibroblasts. sst2A staining in myofibroblasts may be due to
cross-reactivity to myosin,30 but macrophages have been
shown to express sst2A.
31 Macrophages and choroidal fibro-
blasts are thought to be one of the main sources of VEGF in the
early stage of the disease.6,10,32 Both macrophages and choroi-
dal fibroblasts are also capable of releasing other angiogenic
factors such as tumor necrosis factor (TNF)-a and IGF-I.33
Somatostatin analogues have been shown to inhibit the release
TABLE 3. Primers Used for RT-PCR Analysis
Receptor Primer Sequence (5*–3*)* Product Size (base pair)
sst1 Forward ATGGTGGCCCTCAAGGCCGG 318
Reverse CGCGGTGGCGTAATAGTCAA
sst2A Forward GCCAAGATGAAGACCATCAC 414
Reverse GATGAACCCTGTGTACCAAGC
sst3 Forward CCAACGTCTACATCCTCAACC 314
Reverse TCCCGAGAAGACCACCAC
sst4 Forward ATCTTCGCAGACACCAGACC 321
Reverse ATCAAGGCTGGTCACGACGA
sst5 Forward CGTCTTCATCATCTACACGG 226
Reverse CCGTCTTCATCATCTACACGG
SS14 Forward GATGCTGTCCTGCCGCCTCCAG 349
Reverse ACAGGATGTGAAAGTCTTCCA
HPRT Forward CAGGACTGAACGTCTTGCTC 413
Reverse CAAATCCAACAAAGTCTGGC
The sequences of the primers for sst1 were derived and adapted from Wulfsen et al.,
41 for sst5 from
Kubota et al.,42 and all others were designed by use of the Primer3! software (http://www-genome.wi.
mit.edu/genome_software/other/primer3.html) and the appropriate GenBank entries. SS14, somatostatin;
HPRT, hypoxanthine-guanine phosphoribosyl transferase.
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of macrophage and monocyte products such as TNF-a, inter-
leukin (IL)-1b, IL-6 and IL-8 in vitro,34,35 although there are also
conflicting data.36 The functional role of somatostatin with
regard to the angiogenic factor synthesis and release has to be
established.
In the overlying neuroretina of eyes with CNV, we found
no obvious change of sst2A expression and localization in
comparison to normal eyes. This is in contrast to VEGF expres-
sion in neuronal tissue, which is upregulated under hypoxic
circumstances.3,8 This may indicate that the function of soma-
tostatin on neuronal tissue is not influenced by hypoxic retinal
disease. However, some care should be taken when interpret-
ing these results, because they are semiquantitatively deter-
mined. It has recently been shown in a transgenic mouse
model that inhibition of GH, mediated by IGF-I, can inhibit
ischemia-induced retinal neovascularization in vivo, but it does
not reduce hypoxia-induced VEGF mRNA or protein levels. It
FIGURE 1. Immunolocalization of sst2A in posterior pole of normal eyes and eyes with different stages of
ARM. Immunohistochemistry was performed on paraffin-embedded tissue, and visualized with an alkaline
phosphatase detection system using a red chromogen. (A) Positive staining of normal neuroretina, with
strong sst2A expression in the inner plexiform layer (IPL) and moderate expression in the outer plexiform
layer and the cellular membrane of the inner nuclear layer (INL). (B) sst2A staining of normal RPE, showing
the membranous staining pattern on the apical side. (C) sst2A staining of an eye with early ARM, showing
negative staining BLD and soft drusen (#). (D) Negative control staining of CNV (p) in eye 13 with peptide
blocking. (E through H) sst2A staining of CNV (p) in eyes with AMD. Upper pictures are overviews; lower
pictures are details. (E) sst2A staining of a surgically excised fibrovascular CNV (eye 7), with many positive
fibroblast-like cells. (F) sst2A staining of a fibrovascular CNV (eye 5) and (G) of a mixed fibrovascular and
fibrocellular CNV (eye 13). Long arrows: Positive endothelium of newly formed vessels; short arrows:
positive fibroblast-like cells; p: CNV. (H) Staining of a fibrocellular CNV (eye 16), with negative endothelial
cells (white arrow) and fibroblast-like cells. ONL, outer nuclear layer; PR, photoreceptor layer; RPE, retinal
pigment epithelium; CH, choroid; BM, Bruch’s membrane; NR, overlying neuroretina. Original magnifi-
cation, (A) 3200; (B through H) 3400; (E, overview) 3100; (F through H, overviews) 3200.
FIGURE 2. Expression of sst receptor subtype mRNA in the posterior
pole of a normal human eye, detected by RT-PCR. sst1, sst2A, and sst3
were detected. Signals for sst4 and sst5 were too low to detect or
absent. mRNA for somatostatin (SS14) was also detected. HPRT was
used as internal control. Marker, 100 bp.
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has been postulated that GH-IGF-I and VEGF have distinct
functions in the control of angiogenesis: VEGF may control
acute oxygen regulation, whereas IGF-I may control neovascu-
larization on the basis of availability of nutrients for cell divi-
sion.14 Our findings support the hypothesis that somatostatin
and VEGF have distinct functions in the control of angio-
genesis.
We confirmed local synthesis of sst2A in the macula of
normal human eyes with RT-PCR. We also demonstrated the
expression of mRNA encoding for sst subtypes 1 and 3. In rats,
sst2 appeared to be the major subtype in the retina, but all
other subtypes were expressed in retina and posterior pole as
well.17 Differential expression of sst has also been described
previously in the immune system.37 We also found mRNA
expression of the neuropeptide somatostatin in the human
macula. Production of somatostatin in the retina has been
shown in rats with Northern blot analysis hybridization and
mRNA in situ hybridization.38–40 The production of both so-
matostatin and its receptors simultaneously suggests an auto-
crine action of somatostatin in the human retina.
From our findings we conclude that the sst2A receptor in
choroid and retina of early ARM and nonneovascular AMD is
localized similar to normal controls. In eyes with CNV, the
sst2A receptor is strongly expressed in the fibrovascular phase
of CNV, as well as in intrachoroidal myofibroblasts. mRNA of
sst subtypes 1, 2A, and 3, as well as mRNA of somatostatin are
expressed in the macula of the normal human eye. The func-
tional role of somatostatin with regard to the synthesis and
release of angiogenic factors has to be established. Because of
the sst expression in CNV, somatostatin analogues may be an
effective therapy in early stages of CNV in AMD.
Acknowledgments
The authors thank Frieda van der Ham and Diana Mooij for technical
assistance, Frank van der Panne and Huib de Bruin for photography,
and Carolien Klaver for statistical analysis.
References
1. Vingerling JR, Dielemans I, Hofman A, et al. Prevalence of age-
related maculopathy in the Rotterdam Study. Ophthalmology.
1995;102:205–210.
2. D’Amore PA. Mechanisms of retinal and choroidal neovasculariza-
tion. Invest Ophthalmol Vis Sci. 1994;35:3974–3979.
3. Kliffen M, Sharma HS, Mooy CM, et al. Increased expression of
angiogenic growth factors in age-related maculopathy. Br J Oph-
thalmol. 1997;81:154–162.
4. Frank RN, Amin RH, Eliott D, et al. Basic fibroblast growth factor
and vascular endothelial growth factor are present in epiretinal
and choroidal neovascular membranes. Am J Ophthalmol. 1996;
122:393–403.
5. Kvanta A, Algvere PV, Berglin L, et al. Subfoveal fibrovascular
membranes in age-related macular degeneration express vascular
endothelial growth factor. Invest Ophthalmol Vis Sci. 1996;37:
1929–1934.
6. Yi X, Ogata N, Komada M, et al. Vascular endothelial growth factor
expression in choroidal neovascularization in rats. Graefes Arch
Clin Exp Ophthalmol. 1997;235:313–319.
7. Pe’er J, Folberg R, Itin A, et al. Vascular endothelial growth factor
upregulation in human central retinal vein occlusion. Ophthalmol-
ogy. 1998;105:412–426.
8. Pe’er J, Shweiki D, Itin A, et al. Hypoxia-induced expression of
vascular endothelial growth factor by retinal cells is a common
factor in neovascularizing ocular diseases. Lab Invest. 1995;72:
638–644.
9. Lopez PF, Sippy BD, Lambert HM, et al.. Transdifferentiated retinal
pigment epithelial cells are immunoreactive for vascular endothe-
lial growth factor in surgically excised age-related macular degen-
eration-related choroidal neovascular membranes. Invest Ophthal-
mol Vis Sci. 1996;37:855–868.
10. Ishibashi T, Hata Y, Yoshikawa H, et al. Expression of vascular
endothelial growth factor in experimental choroidal neovascular-
ization. Graefes Arch Clin Exp Ophthalmol. 1997;235:159–167.
11. Amin R, Puklin JE, Frank RN. Growth factor localization in choroi-
dal neovascular membranes of age-related macular degeneration.
Invest Ophthalmol Vis Sci. 1994;35:3178–3188.
12. Kitaoka T, Morse LS, Schneeberger S, et al. Expression of FGF5 in
choroidal neovascular membranes associated with ARMD. Curr
Eye Res. 1997;16:396–399.
13. Reddy VM, Zamora RL, Kaplan HJ. Distribution of growth factors
in subfoveal neovascular membranes in age-related macular degen-
eration and presumed ocular histoplasmosis syndrome. Am J Oph-
thalmol. 1995;120:291–301.
14. Smith LEH, Kopchick JJ, Chen W, et al. Essential role of growth
hormone in ischemia-induced retinal neovascularization. Science.
1997;276:1706–1709.
15. Johnson J, Wong H, Walsh JH, Brecha NC. Expression of the
somatostatin subtype 2A receptor in the rabbit retina. J Comp
Neurol. 1998;393:93–101.
16. Helboe L, Moller M. Immunohistochemical localization of soma-
tostatin receptor subtypes sst1 and sst2 in the rat retina. Invest
Ophthalmol Vis Sci. 1999;40:2376–2382.
17. Mori M, Aihara M, Shimizu T. Differential expression of somatosta-
tin receptors in the rat eye: sstR4 is intensely expressed in the
iris/ciliary body. Neurosci Lett. 1997;223:185–188.
18. van der Schaft TL, de Bruijn WC, Mooy CM, et al. Histologic
features of the early stages of age-related macular degeneration: a
statistical analysis. Ophthalmology. 1992;99:278–286.
19. Grossniklaus HE, Gass JDM. Clinicopathologic correlations of sur-
gically excised type 1 and type 2 submacular choroidal neovascu-
lar membranes. Am J Ophthalmol. 1998;126:59–69.
20. Grossniklaus HE, Green R. Histopathologic and ultrastructural find-
ings of surgically excised choroidal neovascularization. Submacu-
lar Surgery Trials Research Group. Arch Ophthalmol. 1998;116:
745–749.
21. Gu Y-Z, Schonbrunn A. Coupling specificity between somatostatin
receptor sst2A and G proteins: isolation of the receptor-G protein
complex with a receptor antibody. Mol Endocrinol. 1997;11:527–
537.
22. Hofland LJ, Liu Q, Van Koetsveld PM, et al. Immunohistochemical
detection of somatostatin receptor subtypes sst1 and sst2A in
human somatostatin receptor positive tumors. J Clin Endocrinol
Metab. 1999;84:775–780.
23. Ferone D, van Hagen PM, van Koetsveld PM, et al. In vitro char-
acterization of somatostatin receptors in the human thymus and
effects of somatostatin and octreotide on cultured thymic epithe-
lial cells. Endocrinology. 1999;140:373–380.
24. Sagar SM, Marshall PE, Onesti ST, et al. Somatostatin immunoreac-
tivity in the rabbit retina. Invest Ophthalmol Vis Sci. 1986;27:316–
322.
25. Zalutsky RA, Miller RF. The physiology of somatostatin in the
rabbit retina. J Neurosci. 1990;10:383–393.
26. Grant MB, Caballero S, Millard WJ. Inhibition of IGF-I and b-FGF
stimulated growth of human retinal endothelial cells by the soma-
tostatin analogue, octreotide: a potential treatment for ocular neo-
vascularization. Regul Pept. 1993;48:267–278.
27. Mallet B, Vialettes B, Haroche S, et al. Stabilization of severe
proliferative diabetic retinopathy by long-term treatment with SMS
201–995. Diabetes Metab. 1992;18:438–444.
28. Shumack SL, Grossman LD, Chew E, et al. Growth hormone sup-
pression and nonproliferative diabetic retinopathy: a preliminary
feasibility study. Clin Invest Med. 1990;5:287–292.
29. Kirkegaard C, Norgaard K, Snorgaard O, et al. Effect of one year
continuous subcutaneous infusion of a somatostatin analogue,
octreotide, on early retinopathy, metabolic control and thyroid
function in type I (insulin-dependent) diabetes mellitus. Acta En-
docrinol (Copenh). 1990;122:766–772.
30. Reubi JC, Laissue JA, Waser B, et al. Immunohistochemical detec-
tion of somatostatin sst2A receptors in the lymphatic, smooth
muscular, and peripheral nervous systems of the human gastroin-
2334 Lambooij et al. IOVS, July 2000, Vol. 41, No. 8
testinal tract: facts and artifacts. J Clin Endocrinol Metab. 1999;
84:2942–2950.
31. Ten Bokum AMC, Hofland LJ, de Jong G, et al. Immunohistochem-
ical localization of somatostatin receptor sst2A in sarcoid granulo-
mas. Eur J Clin Invest. 1999;29:630–636.
32. Kvanta A. Expression and regulation of vascular endothelial
growth factor in choroidal fibroblasts. Curr Eye Res. 1995;14:
1015–1020.
33. Sunderkotter C, Goebeler M, Schulze–Osthoff K, et al. Macro-
phage-derived angiogenesis factors. Rev Pharmacol Ther. 1991;
51:195–216.
34. ChaoTC, Cheng HP, Walter RJ. Somatostatin and macrophage
function: modulation of hydrogen peroxide, nitric oxide and tu-
mor necrosis factor release. Regul Pept. 1995;58:1–10.
35. Peluso G, Petillo O, Melone MA, et al. Modulation of cytokine
production in activated human monocytes by somatostatin. Neu-
ropeptides. 1996;30:443–451.
36. Komorowski J, Stepien H. Somatostatin stimulates the release of
interleukin-6 from human peripheral blood monocytes in vitro.
Neuropeptides. 1995;29:77–81.
37. Ten Bokum AMC, Lichtenauer–Kaligis EGR, Melief MJ, et al. Soma-
tostatin receptor subtype expression in cells of the rat immune
system during adjuvant arthritis. J Endocrinol. 1999;161:167–175.
38. Ferriero DM, Head VA, Edwards RH, Sagar SM. Somatostatin mRNA
and molecular forms during development of the rat retina. Brain
Res Dev Brain Res. 1990;57:15–19.
39. Larsen JN, Bersani M, Olcese J, Holst JJ, Moller M. Somatostatin and
prosomatostatin in the retina of the rat: an immunohistochemical,
in-situ hybridization, and chromatographic study. Vis Neurosci.
1990;5:441–452.
40. Yamaguchi K, Gaur VP, Spira AW, Turner JE. Cellular localization
of somatostatin mRNA in rat retina. Neuropeptides. 1990;17:13–
16.
41. Wulfsen I, Meyerhof W, Fehr S, Richter D. Expression pattern of
rat somatostatin receptor genes in pre- and postnatal brain and
pituitary. J Neurochem. 1993;61:1549–1552.
42. Kubota A, Yamada Y, Kagimoto S, et al. Identification of soma-
tostatin receptor subtypes and an implication for the efficacy of
somatostatin analogue SMS 201–995 in treatment of human endo-
crine tumors. J Clin Invest. 1994;93:1321–1325.
IOVS, July 2000, Vol. 41, No. 8 Somatostatin Receptors in Choroidal Neovascularization 2335
